Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
Marketing Authorisation Application for naloxegol accepted by European Medicines Agency
-
Marketing Authorisation Application for olaparib accepted by European Medicines Agency
-
New hypoglycemia and pancreatitis subanalyses from the Onglyza® (saxagliptin) SAVOR cardiovascular outcomes trial presented at the 49th annual meeting of the European Association for the Study of Diabetes (EASD)
-
New Phase III data showed dapagliflozin significantly reduced HBA1C compared to placebo at 24 weeks in patients with type 2 diabetes inadequately controlled with the combination of metformin plus sulfonylurea
-
Fluenz Tetra, four-strain nasal spray vaccine, receives positive opinion in EU from CHMP for the prevention of seasonal influenza in children
-
FDA accepts new drug application for investigational compound Epanova for the treatment of severe hypertriglyceridaemia
-
US appeals court issues temporary injunction against Hanmi’s 505(b)2 NDA Esomeprazole Strontium
-
AstraZeneca and Merck enter licence agreement for investigational oral WEE1 kinase inhibitor therapy for cancer
-
AstraZeneca initiates Phase III clinical programme for olaparib, a treatment in development for patients with BRCA mutated ovarian cancer
-
ONGLYZA® (saxagliptin) achieves primary safety endpoint, demonstrating no increased risk for cardiovascular death, heart attack or stroke in SAVOR cardiovascular outcomes trial
Latest articles and press releases
All of our latest press releases and articles are available to explore
